New kidney drug trial aims to control IgA nephropathy Long-Term

NCT ID NCT07616700

Recruiting now Disease control Sponsor: Haisco Pharmaceutical Group Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 02, 2026 · Last updated Jun 12, 2026 · Updated 2 times

Summary

This study tests a new tablet, HSK39297, for long-term safety and effectiveness in people with IgA nephropathy, a kidney disease. About 73 adults who completed a prior study will take the drug daily, with a possible dose increase if needed. The main goal is to check for side effects, while also monitoring kidney function and protein levels in urine over time.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for IGA NEPHROPATHY (IGAN) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Peking University First Hospital
COMPLETED

Beijing, China
Peking University First Hospital
RECRUITING

Beijing, China

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

IGA NEPHROPATHY (IGAN)

Conditions inferred from the trial description

These were inferred from the trial's summary, not listed by the trial registrant.

PRIMARY IGA NEPHROPATHY